Head-To-Head Comparison: IceCure Medical (ICCM) and Its Rivals

IceCure Medical (NASDAQ:ICCM) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare IceCure Medical to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings for IceCure Medical and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1	1	2	0	2.25
IceCure Medical Competitors	4264	10498	18235	825	2.46

IceCure Medical currently has a consensus price target of $30.00, indicating a potential upside of 3,622.08%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 18.61%. Given IceCure Medical’s higher possible upside, equities research analysts clearly believe IceCure Medical is more favorable than its peers.

Risk and Volatility

IceCure Medical has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, IceCure Medical’s peers have a beta of 2.56, meaning that their average share price is 156% more volatile than the S&P 500.

Institutional & Insider Ownership

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 2.4% of IceCure Medical shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares IceCure Medical and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
IceCure Medical	$3.38 million	-$15.06 million	-0.09
IceCure Medical Competitors	$1.88 billion	$139.14 million	11.18

IceCure Medical’s peers have higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares IceCure Medical and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
IceCure Medical Competitors	-278.24%	-150.08%	-21.87%

Summary

IceCure Medical peers beat IceCure Medical on 12 of the 13 factors compared.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.